Mar 26, 2009 - Spectrum Pharmaceuticals, Inc. announced today that it received notification that the U.S. FDA has accepted for filing and review the supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection in combination with 5-FU containing regimens in advanced metastatic colorectal cancer.
the details can be read here.
No comments:
Post a Comment